Tradestie Institutional Equity Comparison Engine

MGNX vs MESO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MGNX Overall Edge

MGNX Captures Institutional Edge (4โ€“0 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MacroGenics, Inc. (MGNX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MGNX trades at 61.0x Forward P/E with -21.7% operating margin (+378.0% YoY revenue) versus MESO at N/M Forward P/E and -42.6% operating margin (+390.7% YoY). In options structure, MGNX sits in BREAKDOWN (1st %ile IV; Dealer Gamma Walls on Pro) against MESO sits in UNCLASSIFIED (37th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MGNX
MGNX 61.0x vs MESO N/M Fwd P/E
Growth & Margin Winner MGNX
Op Margin -21.7% vs -42.6% ยท YoY +378.0% vs +390.7%
Momentum & Technical Winner MGNX
1Y +26.6% vs -16.4% ยท 52W Pos 19% vs 6%
Options & Structure Winner MGNX
BREAKDOWN (1st %ile IV) vs UNCLASSIFIED (37th %ile IV)
MGNX NASDAQ
MacroGenics, Inc.
Pharmaceutical Preparations
$2.02
-7.95% 1D
Market Cap $145.9M
1M Return -37.69%
1Y Return +26.56%
Forward P/E 61.0x
Unified AI Score
43.6 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 55.0
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
1M Return -6.1%
1Y Return -16.42%
Forward P/E N/M
Unified AI Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MGNX +26.56% MESO -16.42% Spread: +42.98 pp (MGNX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MGNX TTM Op. Margin: -21.7% MESO TTM Op. Margin: -42.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MGNX vs MESO. Trailing 12-month operating profitability (MGNX -21.7% vs MESO -42.6%) and valuation multiples (MGNX 61.0x vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MGNX (6) vs MESO (4)
Institutional Metric MGNX MESO Criterion Row Winner
Market Capitalization Scale $145.9M $1.7B Larger Scale MESO
Trailing P/E Ratio Valuation 61.0x N/M Lower Multiple MGNX
Forward P/E Ratio Valuation 61.0x N/M Lower Multiple MGNX
Revenue Growth (YoY) Growth +378.0% +390.7% Higher Growth MESO
Operating Margin (TTM) Profitability -21.7% -42.6% Higher Margin MGNX
Net Profit Margin Profitability -8.3% -47.8% Higher Margin MGNX
Return on Equity (ROE) Capital Efficiency -225.9% -9.9% Higher ROE MESO
52-Week Range Position Momentum 19% ($1โ€“$5) 6% ($12โ€“$22) Stronger Trend MGNX
Beta / 30D Volatility Risk Regime 1.37ฮฒ ยท 148% Vol 1.18ฮฒ ยท 78% Vol Lower Realized Risk MESO
Unified Institutional Score Composite Signal 43.6 / 100 (HOLD) 35.5 / 100 (SELL) Higher Composite MGNX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MGNX vs MESO Buy Guide
MGNX BREAKDOWN
122d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 1st %ile
IV Regime Compressed (<25th %ile)
Live MGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MESO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 37th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MESO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MGNX nor MESO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.